Loading...
Aspirin as a chemoprevention agent for colorectal cancer.
Lee, Chun Seng McNamara, Deirdre O'Morain, Colm A
Lee, Chun Seng
McNamara, Deirdre
O'Morain, Colm A
Advisors
Editors
Other Contributors
Date
2012-11
Date Submitted
Keywords
Other Subjects
Subject Mesh
Animals
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Aspirin
Colorectal Neoplasms
Cost-Benefit Analysis
Humans
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Aspirin
Colorectal Neoplasms
Cost-Benefit Analysis
Humans
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Colorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature [1, 2]. It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.
Language
en
ISSN
1875-5453
eISSN
ISBN
DOI
PMID
22493984